Although CD4 T cells and MHC-II NeoAgs are critical components of anti-tumor immunity20,48,80–86, we specifically chose to utilize an SLP vaccine against a single MHC-I NeoAg to definitively link the MHC-I NeoAg vaccine response to a specific defined NeoAg. This evidence concerns the gene CD4 and neoplasm.